ClinicalTrials.gg
RecruitingNCT04844866DALY 2-EUUpdated Jun 10, 2026

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

A Phase 2 interventional study of MB-CART2019.1 and Standard of Care in Diffuse Large B-cell Lymphoma, sponsored by Miltenyi Biomedicine GmbH. Recruiting at 51 sites in 14 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Miltenyi Biomedicine GmbH · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2021; still recruiting 5 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
213
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 108 studies in Lymphoma, Large B-Cell, Diffuse with a site in Germany — 15 open to participants now, 27 under way, 7 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Germany.

Planned enrollment
42nd of 100
213 · median 156
Started
2021
with 5 others
Phase 2
30 of 108
4 open now
Primary completion
2025-01
later than 0 of 26 live
Registered
85th of 108
by date

Among the 108 studies in Lymphoma, Large B-Cell, Diffuse with a site in Germany, this one is the 42nd largest by planned enrollment of the 100 interventional ones that give a count, is one of 6 that started in 2021, is one of 30 in phase 2, reaches primary completion later than 0 of the 26 other live ones, and was the 85th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

15 of the 108 studies in Lymphoma, Large B-Cell, Diffuse with a site in Germany are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Lymphoma, Large B-Cell, Diffuse with a site in Germany, or all of them as a file.
02

Study summary

In the current protocol version, there are two parts. Part I is a pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma, who are not eligible for high-dose chemotherapy and autologous stem cell transplantation.

Part II is a Phase II single-arm, open-label, multi-centre study evaluating the efficacy and safety of MB-CART2019.1 in younger, fit participants with R-R DLBCL. Part II will start after completion of enrolment in Part I.

Read the detailed description

In Part I, the study should determine superiority of MB-CART2019.1 treatment compared to SoC therapy with R-GemOx (rituximab, gemcitabine and oxaliplatin) with respect to event-free survival in second-line therapy in participants with R-R DLBCL, who are non-eligible for high-dose chemotherapy and autologous stem cell transplantation.

MB-CART2019.1 is designed to effectively target malignant B cells in patients suffering from late stage haematological B-cell malignancies. MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis and processed by using the CliniMACS Prodigy®. Patients who are suitable for this study will be randomized 1:1 to either MB-CART2019.1 or SoC. Both treatment arms are unblinded.

MB-CART2019.1 arm: Single infusion of fresh formulation of 2.5 × 10\^6 CAR-transduced autologous T cells. IMP is only to be administered after a lymphodepleting chemotherapy with fludarabine and cyclophosphamide. For MB-CART2019.1 production, patients will undergo a leukapheresis.

SoC arm: R-GemOx (8 cycles of 14 days each) or (10% of SoC arm) BR (Bendamustine/Rituximab) + polatuzumab vedotin (6 cycles of 21 days each). Participants from the SoC arm are allowed to be treated with MB-CART2019.1 upon request by the investigator if at least one of the following criteria is confirmed by the IRC:

  • Relapse or progression occurring at any time within 1 year after randomisation.
  • Failure to achieve PR or CR at or beyond Week 8 after randomisation (after 4 cycles of R-GemOx or 3 cycles of BR plus polatuzumab vedotin) and the start of a new anti-lymphoma therapy is warranted.

The duration of the active part of the study for each individual participant from screening to the end of the 1-year follow-up after infusion of MB-CART2019.1 cells (experimental arm) or the start of SoC therapy (comparator arm) will be approximately 55 weeks. The LTFU in Year 2 after infusion of MB-CART2019.1 cells or the start of treatment in the comparator arm will not be part of the active part of the clinical study and will be reported separately.

In Part II, the study should evaluate the efficacy of MB-CART2019.1 in younger, fit participants with R-R DLBCL. Approximately 45 participants will be enrolled in this part to obtain 40 evaluable participants for the analysis of the primary endpoint.

Screening will take place within 4 weeks before leukapheresis. In individual cases, the sponsor may agree to extending the screening period by up to two weeks. Only participants satisfying all protocol inclusion and none of the exclusion criteria will be included in the clinical study.

03

Conditions studied

  • Diffuse Large B-cell Lymphoma

Keywords

  • CAR T cells
  • chimeric antigen receptor
  • MB-CART2019.1
  • CD20
  • CD19
  • relapsed refractory
  • Diffuse Large B-cell Lymphoma
  • DLBCL
  • Non-Hodgkin Lymphoma
  • NHL
  • zamtocabtagene autoleucel
  • blood cancer
  • LBCL
  • Follicular Lymphoma 3B
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Part I:

  1. proven DLBCL and associated subtypes, according to the World Health Organization (WHO) 2016 classification including:

    • DLBCL not otherwise specified (NOS).
    • High-grade B-cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements with DLBCL/blastoid/intermediate histology or HGBL with MYC and BCL2 and/or BCL6 rearrangements (double hit lymphoma/triple hit lymphoma).
    • High-grade BCL, NOS.
    • Primary (thymic) large mediastinal BCL.
    • Disease transformed from an earlier diagnosis of low-grade lymphoma (e.g. an indolent pathology such as follicular lymphoma, marginal zone lymphoma) into DLBCL with DLBCL disease progression subsequent to DLBCL-directed systemic treatment.
    • Follicular lymphoma Grade 3B.
  2. disease after chemoimmunotherapy:

    • Refractory disease defined as no CR to first-line therapy (e.g. R-CHOP [rituximab, cyclophosphamide, daunorubicin, vincristine and prednisone]).

      • Progressive disease (PD) after at least 2 full cycles of first-line therapy.
      • Stable disease (SD) after 4 cycles of first-line therapy.
      • PR as best response after at least 6 cycles of first-line therapy and -proven persistent disease (except where prohibited due to comorbidities) within ≤ 24 months from the start of the first-line therapy.
    • Relapsed disease defined as complete remission to first-line therapy followed by biopsy-proven disease progression (except where prohibited due to comorbidities) within ≤ 24 months from the start of the first-line therapy.
  3. Participants must have received adequate first-line therapy containing at least the combination of an anthracycline-based regimen and rituximab (anti-CD20 monoclonal antibody). Local therapies (e.g. radiotherapies) will not be considered as line of therapy if performed during the same line of treatment.
  4. Archival paraffin-embedded tumour tissue acquired ≤ 2 years (preferred: ≤ 2 months) prior to screening for the central pathology review to confirm DLBCL diagnosis must be made available for participation in this study. If archival paraffin-embedded tumour tissue is not available, fresh tumour tissue sample (preferred) or core-needle biopsy must be made available for the central pathology review.
  5. Participants deemed ineligible to receive HDC followed by based on the treating physician's assessment and meeting the following criteria:

    EITHER

    • Age ≥ 18 years and

      • Prior ASCT (as first-line consolidation) or
      • Haematopoietic cell transplantation-specific comorbidity index (HCT-CI) > 3. OR
    • Age ≥ 65 years and ≥ 1of the criteria below:

      • Impaired cardiac function ( [LVEF] \< 50%), or
      • Impaired renal function (estimated [eGFR] \< 60 mL/min) calculated according to the modified Modification of Diet in Renal Disease (MDRD) formula, or
      • Impaired pulmonary function (diffusing capacity for carbon monoxide or \< 80%) or dyspnoea on slight activity, or
      • (ECOG) performance status > 1. OR
    • Age ≥ 70 years. Documentation of the reason for ineligibility for ASCT must be present in the participant's source data.

    In addition, all participants must fulfil the following criteria:

  6. Age ≥ 18 years.
  7. according to Lugano criteria. The lesion must be measurable (nodes > 1.5 cm in the long axis; extranodal lesions > 1 cm in the long axis) and positive on a positron emission tomography scan.
  8. Estimated of > 3 months for other reasons than the primary disease.
  9. Women of (WOCBP) must agree to use highly effective measures (Pearl index \< 1) or practice true sexual abstinence from any heterosexual intercourse (True abstinence is only acceptable if it is in line with the preferred and usual life style of the participant.) or must have a vasectomised partner as the sole sexual partner (The vasectomised partner must have received medical assessment of the surgical success.) for at least 1 month before the study start, during the study and in the 12 months following the last dose of study treatment. A woman is considered a WOCBP, i.e. fertile, following menarche and until becoming unless permanently sterile. Highly effective methods of contraception include hormonal contraceptives associated with inhibition of ovulation (oral, intravaginal, transdermal, injectable, implantable) and intrauterine devices or systems (e.g. hormonal and non-hormonal) and bilateral tubal occlusion. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A post-menopausal state is defined as no menses for 12 months without an alternative medical cause. WOCBP who want to become pregnant after completing treatment should seek advice about oocyte cryoconservation prior to treatment because of possible irreversible infertility. WOCBP must refrain from egg donation throughout the study until 12 months after the last dose of study treatment.

    Men with non-pregnant WOCBP partners must agree to use highly effective contraceptive measures (Pearl index \< 1, e.g. spermicide and condom or other highly effective contraceptive measures (Pearl index \< 1) taken by their WOCBP partner) or practice true sexual abstinence from any heterosexual intercourse (True abstinence is only acceptable if it is in line with the preferred and usual life style of the participant.), unless they are surgically sterile (meaning at least 2 consecutive analyses following vasectomy demonstrate absence of sperms in the ejaculate), during the study and in the 12 months following the last dose of study treatment. Men should seek advice about sperm conservation prior to treatment because of possible irreversible infertility. Men must furthermore refrain from sperm donation throughout the study until 12 months after the last administration of study treatment.

  10. In the opinion of the investigator, the participant must be able to comply with all study-related procedures, medication use and evaluations.
  11. Mental capacity and legal ability to consent to participation in the clinical study.

Criteria for Exclusion:

  1. for R-GemOx, BR plus polatuzumab vedotin, cyclophosphamide and fludarabine as judged by the treating physician.
  2. Prior chimeric antigen receptor therapy or other genetically modified T-cell therapy.
  3. Participants who have received more than one line of treatment for DLBCL or associated subtypes.
  4. Prior haematopoietic stem cell transplantation (HSCT; as first-line consolidation) \< 3 months at the time of leukapheresis.
  5. ECOG performance status > 2.
  6. \< 1,000/μL (unless secondary to bone marrow involvement by DLBCL as demonstrated by bone marrow biopsy).
  7. count \< 50,000/μL (unless secondary to bone marrow involvement by DLBCL as demonstrated by bone marrow biopsy).
  8. Absolute lymphocyte count \< 100/μL.
  9. Participants who have central nervous system (CNS) lymphoma involvement in present or past medical history.
  10. Participants with the requirement for urgent therapy due to tumour mass effects.
  11. Infection with .
  12. Presence of active or prior or C as indicated by serology (for detailed criteria see Section 10.2.7.10). Treated infection with hepatitis B or C virus unless confirmed to be polymerase chain reaction negative.
  13. Active infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
  14. Active, severe systemic fungal, viral or bacterial infection.
  15. Known history or evidence of severely state, i.e. treatment > 10 mg/day for more than 6 months.
  16. Has received vaccination with 6 weeks prior to randomisation.
  17. Prior CD19-targeted therapy.
  18. Known history or presence of seizure activities or on active anti-seizure medications within the previous 12 months.
  19. History or presence of non-malignant CNS disease that, in the judgement of the investigator, may impair the ability to evaluate neurotoxicity.
  20. Known history or presence of CNS disease, such as multiple sclerosis, optic neuritis or other immunologic or inflammatory disease.
  21. Known history or presence of cerebral vascular accident (CVA) within 12 months prior to randomisation.

    Note: In case of history of CVA > 12 months prior to leukapheresis, then the participant must not have any unstable or life-threatening neurological deficits.

  22. Participants with Richter's transformation or Richter's syndrome.
  23. Participants who are concurrently on any other experimental treatments or during the previous 4 weeks or 5 half-lives.
  24. Clinical heart failure with class ≥ 2 or LVEF \< 30% or severe cardiac arrhythmias or (resting QTcF ≥ 450 msec [male] or ≥ 460 msec [female] at screening) that would (according to the evaluation of the investigator) face an uncontrollable risk by receiving the medications administered in the trial.
  25. Resting peripheral oxygen saturation \< 90% on room air.
  26. Liver dysfunction as indicated by total > 2.5 × institutional (ULN), and/or alanine aminotransferase > 5 × ULN or typical symptoms like jaundice.
  27. Serum creatinine ≥ 2.0 × ULN or eGFR \< 30 mL/min calculated according to the modified MDRD formula.
  28. Pregnant or breast-feeding women.
  29. Prior history of other than DLBCL. Exceptions include participants who have been free of the disease for ≥ 3 years prior to screening and participants with adequately treated and removed basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, carcinoma in situ of the bladder or incidental histological finding of untreated localised (T1a, T1b or T1c) prostate cancer under surveillance.
  30. History of severe immediate to any medicinal product (IMP), auxiliary medicinal product (AxMP), premedication or rescue medication or its that is scheduled to be given during study participation.
  31. Major surgery less than 30 days before start of treatment.
  32. Any medical condition likely to interfere with assessment of safety or efficacy of study treatment.

Part II:

  1. Histologically proven DLBCL and associated subtypes, according to the WHO 2016 classification including:

    • DLBCL, NOS.
    • HGBL with MYC and BCL2 and/or BCL6 rearrangements with DLBCL/blastoid/intermediate histology or HGBL with MYC and BCL2 and/or BCL6 rearrangements (double hit lymphoma/triple hit lymphoma).
    • High-grade BCL, NOS.
    • Primary (thymic) large mediastinal BCL.
    • Disease transformed from an earlier diagnosis of low-grade lymphoma (e.g., an indolent pathology such as follicular lymphoma, marginal zone lymphoma) into DLBCL with DLBCL disease progression subsequent to DLBCL-directed systemic treatment.
    • Follicular lymphoma Grade 3B.
  2. Relapsed or refractory disease after first-line chemoimmunotherapy:

    • Refractory disease defined as no CR to first-line therapy (e.g., R-CHOP).

      • PD after at least 2 full cycles of first-line therapy.
      • SD after 4 cycles of first-line therapy.
      • PR as best response after at least 6 cycles of first-line therapy and biopsy-proven persistent disease (except where prohibited due to comorbidities) within ≤ 12 months after completion of first-line treatment.
    • Relapsed disease defined as complete remission to first-line therapy followed by biopsy-proven disease progression (except where prohibited due to comorbidities) within ≤ 12 months after completion of first-line treatment.
  3. Participant must have received adequate first-line therapy containing at least the combination of an anthracycline-based regimen and rituximab (anti-CD20 monoclonal antibody). Local therapies (e.g., radiotherapies) will not be considered as line of therapy if performed during the same line of treatment.
  4. Archival paraffin-embedded tumour tissue acquired ≤ 2 years (preferred: ≤ 2 months) prior to screening for the central pathology review to confirm DLBCL diagnosis must be made available for participation in this study. If archival paraffin-embedded tumour tissue is not available, fresh tumour tissue sample (preferred) or core-needle biopsy must be made available for the central pathology review.
  5. Measurable disease according to Lugano criteria. The lesion must be measurable (nodes > 1.5 cm in the long axis; extranodal lesions > 1 cm in the long axis) and positive on a positron emission tomography scan.
  6. Approved treatment options not suitable according to investigator's assessment.

    In addition, all participants must fulfil the following criteria:

  7. Age ≥ 18 and ≤ 70 years.
  8. Estimated life expectancy of > 3 months for other reasons than the primary disease.
  9. ECOG 0-1.
  10. Adequate bone marrow function, defined as:

    • Absolute neutrophil count ≥ 1,000/μL (unless secondary to bone marrow involvement by DLBCL as demonstrated by bone marrow biopsy).
    • Platelet count ≥ 50,000/μL (unless secondary to bone marrow involvement by DLBCL as demonstrated by bone marrow biopsy).
    • Absolute lymphocyte count ≥ 100/μL.
  11. Adequate organ function, defined as:

    • New York Heart Association class \< 2 or LVEF ≥ 50%.
    • No severe cardiac arrhythmias or QT prolongation (resting QTcF \< 450 msec [male] or \< 460 msec [female] at screening).
    • No pleural effusion or pericardial effusion.
    • Resting peripheral oxygen saturation ≥ 92% on room air.
    • Total bilirubin ≤ 2.0 × ULN, AST and/or ALT ≤ 5 × ULN
    • Serum creatinine \< 1.0 × ULN or eGFR (according to modified MDRD formula) ≥ 60 mL/min.
  12. WOCBP must agree to use highly effective contraceptive measures (Pearl index \< 1) or practice true sexual abstinence from any heterosexual intercourse (True abstinence is only acceptable if it is in line with the preferred and usual life style of the participant.) or must have a vasectomised partner as the sole sexual partner (The vasectomised partner must have received medical assessment of the surgical success.) for at least 1 month before the study start, during the study and in the 12 months following the last dose of study treatment. A woman is considered a WOCBP, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Highly effective methods of contraception include hormonal contraceptives associated with inhibition of ovulation (oral, intravaginal, transdermal, injectable, implantable) and intrauterine devices or systems (e.g., hormonal and non-hormonal) and bilateral tubal occlusion. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A post-menopausal state is defined as no menses for 12 months without an alternative medical cause. WOCBP who want to become pregnant after completing treatment should seek advice about oocyte cryoconservation prior to treatment because of possible irreversible infertility. WOCBP must refrain from egg donation throughout the study until 12 months after the last dose of study treatment. Men with non-pregnant WOCBP partners must agree to use highly effective contraceptive measures (Pearl index \< 1, e.g., spermicide and condom or other highly effective contraceptive measures (Pearl index \< 1) taken by their WOCBP partner) or practice true sexual abstinence from any heterosexual intercourse (True abstinence is only acceptable if it is in line with the preferred and usual life style of the participant.), unless they are surgically sterile (meaning at least 2 consecutive analyses following vasectomy demonstrate absence of sperms in the ejaculate), during the study and in the 12 months following the last dose of study treatment. Men should seek advice about sperm conservation prior to treatment because of possible irreversible infertility. Men must furthermore refrain from sperm donation throughout the study until 12 months after the last administration of study treatment.
  13. In the opinion of the investigator, the participant must be able to comply with all study-related procedures, medication use and evaluations.
  14. Mental capacity and legal ability to consent to participation in the clinical study.

Criteria for Exclusion:

  1. Contraindications for cyclophosphamide and fludarabine as judged by the treating physician.
  2. Prior chimeric antigen receptor therapy or other genetically modified T-cell therapy.
  3. Participants who have received more than one line of prior therapy for DLBCL or associated subtypes.
  4. Prior HSCT (as first-line consolidation) \< 3 months at the time of leukapheresis.
  5. Participants who have CNS lymphoma involvement in present or past medical history.
  6. Participants with the requirement for urgent therapy due to tumour mass effects.
  7. Infection with human immunodeficiency virus.
  8. Presence of active or prior hepatitis B or C as indicated by serology. Treated infection with hepatitis B or C virus unless confirmed to be polymerase chain reaction negative.
  9. Infection with Treponema pallidum (pathogen causing syphilis).
  10. Infection with human T-lymphotropic virus 1.
  11. Active infection with SARS-CoV-2.
  12. Active, severe systemic fungal, viral, or bacterial infection.
  13. Known history or evidence of severely immunocompromised state, i.e. corticosteroid treatment > 10 mg/day for more than 6 months.
  14. Has received vaccination with live virus vaccines within 6 weeks prior to randomisation.
  15. Prior CD19-targeted therapy.
  16. Known history or presence of seizure activities or on active anti-seizure medications within the previous 12 months.
  17. History or presence of non-malignant CNS disease that, in the judgement of the investigator, may impair the ability to evaluate neurotoxicity.
  18. Known history or presence of autoimmune CNS disease, such as multiple sclerosis, optic neuritis or other immunologic or inflammatory disease.
  19. Known history or presence of CVA within 12 months prior to randomisation. Note: In case of history of CVA > 12 months prior to leukapheresis, then the participant must not have any unstable or life-threatening neurological deficits.
  20. Participants with Richter's transformation or Richter's syndrome.
  21. Participants who are concurrently on any other experimental treatments or during the previous 4 weeks or 5 half-lives.
  22. Pregnant or breastfeeding woman.
  23. Prior history of malignancies other than DLBCL. Exceptions include participants who have been free of the disease for ≥ 3 years prior to screening and participants with adequately treated and removed basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, carcinoma in situ of the bladder or incidental histological finding of untreated localised (T1a, T1b or T1c) prostate cancer under surveillance.
  24. History of severe immediate hypersensitivity to any IMP, AxMP, premedication or rescue medication or its excipients that is scheduled to be given during study participation.
  25. Major surgery less than 30 days before start of treatment.
  26. Any medical condition likely to interfere with assessment of safety or efficacy of study treatment.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
213 participants (estimated)

Study arms

  • Experimental
    Part I: CAR T-cell MB-CART2019.1

    Single infusion of 2.5 × 10\^6 CAR-transduced autologous T cells per kg/body weight.

    Genetic: MB-CART2019.1

  • Experimental
    Part II: CAR T-cell MB-CART2019.1

    Single infusion of 2.5 × 10\^6 CAR-transduced autologous T cells per kg/body weight.

    Genetic: MB-CART2019.1

  • Active comparator
    PART I: Standard of Care

    R-GemOx R-Pola

    Drug: Standard of Care

Interventions

  • GeneticMB-CART2019.1

    MB-CART2019.1 is designed to effectively target malignant B cells in patients suffering from late stage haematological B-cell malignancies. MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis and processed by using the CliniMACS Prodigy® device.

    Also known as: Zamtocabtagene Autoleucel, Zamto-cel

  • DrugStandard of Care

    Standard of Care

    Also known as: Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab

06

What researchers measure

Primary outcomes

  1. Part I: Event-free survival

    Event-free survival (EFS), defined as the time between the date of randomisation and the date of objective disease progression, failure to achieve partial response (PR) or complete response (CR) at or beyond Week 8 after randomisation leading to a new anti-lymphoma therapy or death of any cause, whichever occurs first, based on independent review committee (IRC) assessment.

    Time frame: up to 30 weeks after randomisation

  2. Part II: Best objective response rate

    Best objective response rate (BORR), defined as the proportion of participants with at least one CR or PR between the date of MB-CART2019.1 infusion and the date of objective disease progression, the start of new anti-lymphoma therapy or the date of death from any cause, whichever occurs first, based on IRC assessment.

    Time frame: up to 30 weeks after administration of MB-CART2019.1

Secondary outcomes

  1. Part I: Progression-free survival (PFS)

    defined as the time between the date of randomisation and the date of objective disease progression or death of any cause, whichever occurs first, based on IRC assessment.

    Time frame: up to 99 weeks after randomisation

  2. Part I: Best complete response rate

    To evaluate the safety and toxicity of MB-CART2019.1 compared to SoC therapy.

    Time frame: up to 99 weeks after randomisation

  3. Part I: Duration of complete response

    To evaluate the safety and toxicity of MB-CART2019.1 compared to SoC therapy.

    Time frame: up to 91 weeks

  4. Part I: Overall Survival

    To evaluate the safety and toxicity of MB-CART2019.1 compared to SoC therapy.

    Time frame: up to 99 weeks after randomisation

  5. Part II: Duration of Response (DOR)

    defined as the time between the date of a first objective response (CR/PR) after MB-CART2019.1 infusion and the date of assessment of objective disease progression or the date of death

    Time frame: up to 91 weeks

  6. Part II: Progression-free survival (PFS)

    defined as the time between the date of leukapheresis and the date of objective disease progression or death

    Time frame: up to 99 weeks after leukapheresis

  7. Part II: Overall Survival (OS)

    defined as time between the date of leukapheresis and the date of death

    Time frame: up to 99 weeks after leukapheresis

  8. Part II: Best Complete Response Rate (BCRR)

    defined as the proportion of participants with CR between the date of MB-CART2019.1 infusion and the date of objective disease progression, the start of new anti-lymphoma therapy or the date of death

    Time frame: up to 99 weeks after leukapheresis

  9. Part II: Duration of Complete Response (DOCR)

    defined as the time between the date of a first CR and the date of assessment of objective disease progression or the date of death

    Time frame: up to 91 weeks

07

Study locations

39 of 51 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Jan 2025, 40 months.

Of 53 industry-sponsored phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's 40 months is close to that.

Counting every sponsor, half of 264 studies reached it within 52 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2021
First posted
Apr 14, 2021
StartActual
Aug 18, 2021
Primary completionActual
Jan 15, 2025
CompletionEst.
Sep 30, 2031
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04844866
Lead sponsor
Miltenyi Biomedicine GmbH
Collaborators
ICON plc
Responsible party
Sponsor
First posted
Apr 14, 2021
Start date
Aug 18, 2021
Primary completion
Jan 15, 2025
Completion
Sep 30, 2031 (estimated)
Last update
Jun 10, 2026

Study contacts

Mark Hess, Dr.
Contact
mark.hess@miltenyi.com
+49 160 9897 0124
Gregor Zadoyan, Dr.
Contact
gregor.zadoyan@miltenyi.com
+49 2204 8306 ext. 6639
Peter Borchmann, Prof. Dr.
principal investigator · University Hospital Cologne

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion